May 16, 2025

FDA Clears First Blood Test for Alzheimer’s

The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.

Conexiant

May 16, 2025

vNOTES Speeds Bowel, Work Recovery After Hysterectomy

A prospective study found that patients who underwent vNOTES hysterectomy recovered bowel function and returned to work faster than those who had traditional laparoscopic surgery.

Conexiant

May 16, 2025

Long-Term Data Support BCT for BRCA-Mutated Breast Cancer

Researchers found that breast-conserving treatment provided long-term survival outcomes comparable to mastectomy in patients with breast cancer and BRCA1 or BRCA2 pathogenic variants.

Conexiant

May 15, 2025

First Migraine DHE Autoinjector FDA-Approved

FDA approves Brekiya®, a dihydroergotamine mesylate autoinjector for the acute treatment of migraine with or without aura and cluster headaches in adults.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

May 14, 2025

USPSTF: Syphilis Screening During Pregnancy Gets A-Rating

USPSTF reaffirms A-rating for universal syphilis screening during pregnancy as congenital syphilis cases reach a 30-year high.

Conexiant

May 14, 2025

Prenatal Testosterone: Shaping Children's Fitness?

New study finds maternal testosterone exposure during pregnancy affects physical activity in boys and muscle strength in girls at age 7, with potential implications for long-term cardiovascular health.

Conexiant

May 13, 2025

Early Antibiotics Impact Puberty Timing, Study

Infant antibiotic exposure may significantly impact female pubertal timing,

Conexiant

May 13, 2025

Tirzepatide Tops Semaglutide for Weight Loss

In the SURMOUNT-5 trial, tirzepatide led to a 20.2% mean weight loss in adults with obesity—significantly more than the 13.7% achieved with semaglutide.

Conexiant